GSK plc
GSK49.240USD
+0.430+0.88%
Close 12/15, 16:00（ET）Quotes delayed by 15 min
99.12BMarket Cap
13.90P/E TTM
More Details of GSK plc Company
GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.
GSK plc Info
Ticker SymbolGSK
Company nameGSK plc
IPO dateMay 22, 1972
CEOWaterhouse (Deborah)
Number of employees68629
Security typeDepository Receipt
Fiscal year-endMay 22
Address980 Great West Road
CityBRENTFORD
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryUnited Kingdom
Postal codeTW8 9GS
Phone442080475000
Websitehttps://www.gsk.com/
Ticker SymbolGSK
IPO dateMay 22, 1972
CEOWaterhouse (Deborah)
Company Executives of GSK plc
Name
Name/Position
Position
Shareholding
Change
Dr. Hal V. Barron, M.D.
Dr. Hal V. Barron, M.D.
Non-Executive Director
Non-Executive Director
661.21K
+0.43%
Ms. Shobie Ramakrishnan
Ms. Shobie Ramakrishnan
Chief Digital and Technology Officer
Chief Digital and Technology Officer
484.59K
+0.08%
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
38.91K
+0.88%
Ms. Elizabeth McKee (Liz) Anderson
Ms. Elizabeth McKee (Liz) Anderson
Independent Non-Executive Director
Independent Non-Executive Director
3.00K
+0.87%
Dr. Jeannie Lee
Dr. Jeannie Lee
Independent Non-Executive Director and Scientific & Medical Expert
Independent Non-Executive Director and Scientific & Medical Expert
1.58K
+0.83%
Dr. Harry C. (Hal) Dietz
Dr. Harry C. (Hal) Dietz
Independent Non-Executive Director, Scientific and Medical Expert
Independent Non-Executive Director, Scientific and Medical Expert
--
--
Mr. James Ford
Mr. James Ford
Senior Vice President, Group General Counsel, Legal and Compliance
Senior Vice President, Group General Counsel, Legal and Compliance
--
--
Ms. Sally Jackson
Ms. Sally Jackson
Senior Vice President - Global Communications and CEO Office
Senior Vice President - Global Communications and CEO Office
--
--
Dr. Tony Wood, Ph.D.
Dr. Tony Wood, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Julie Brown
Ms. Julie Brown
Chief Financial Officer, Executive Director
Chief Financial Officer, Executive Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Hal V. Barron, M.D.
Dr. Hal V. Barron, M.D.
Non-Executive Director
Non-Executive Director
661.21K
+0.43%
Ms. Shobie Ramakrishnan
Ms. Shobie Ramakrishnan
Chief Digital and Technology Officer
Chief Digital and Technology Officer
484.59K
+0.08%
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
38.91K
+0.88%
Ms. Elizabeth McKee (Liz) Anderson
Ms. Elizabeth McKee (Liz) Anderson
Independent Non-Executive Director
Independent Non-Executive Director
3.00K
+0.87%
Dr. Jeannie Lee
Dr. Jeannie Lee
Independent Non-Executive Director and Scientific & Medical Expert
Independent Non-Executive Director and Scientific & Medical Expert
1.58K
+0.83%
Dr. Harry C. (Hal) Dietz
Dr. Harry C. (Hal) Dietz
Independent Non-Executive Director, Scientific and Medical Expert
Independent Non-Executive Director, Scientific and Medical Expert
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
US
5.49B
51.53%
Rest of world
2.71B
25.44%
Europe
2.45B
23.03%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Nov 15
Updated: Sat, Nov 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Dodge & Cox
3.85%
Fidelity Management & Research Company LLC
2.74%
Fisher Investments
1.58%
PRIMECAP Management Company
1.26%
JTC Employer Solutions Trusteee Ltd
0.72%
Other
89.85%
Shareholders
Shareholders
Proportion
Dodge & Cox
3.85%
Fidelity Management & Research Company LLC
2.74%
Fisher Investments
1.58%
PRIMECAP Management Company
1.26%
JTC Employer Solutions Trusteee Ltd
0.72%
Other
89.85%
Shareholder Types
Shareholders
Proportion
Investment Advisor
9.59%
Investment Advisor/Hedge Fund
7.49%
Research Firm
1.05%
Hedge Fund
0.80%
Bank and Trust
0.10%
Individual Investor
0.06%
Pension Fund
0.05%
Family Office
0.03%
Family Office
0.02%
Other
80.80%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
1474
388.63M
19.14%
-11.70M
2025Q2
1478
378.08M
18.54%
+5.70M
2025Q1
1494
378.46M
18.50%
+5.08M
2024Q4
1481
355.06M
17.14%
+27.38M
2024Q3
1472
319.97M
15.44%
-30.07M
2024Q2
1585
322.06M
15.54%
-29.11M
2024Q1
1617
318.91M
15.39%
-23.52M
2023Q4
1614
299.81M
14.57%
-35.71M
2023Q3
1570
293.92M
14.35%
-37.46M
2023Q2
1545
286.58M
13.99%
-41.88M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Dodge & Cox
78.76M
3.87%
+106.04K
+0.13%
Jun 30, 2025
Fidelity Management & Research Company LLC
51.48M
2.53%
+872.19K
+1.72%
Jun 30, 2025
Fisher Investments
31.34M
1.54%
+1.31M
+4.35%
Jun 30, 2025
PRIMECAP Management Company
27.73M
1.36%
+2.02M
+7.85%
Jun 30, 2025
JTC Employer Solutions Trusteee Ltd
15.00M
0.74%
-262.98K
-1.72%
Jun 30, 2025
Fidelity Institutional Asset Management
9.53M
0.47%
+10.84K
+0.11%
Jun 30, 2025
T. Rowe Price International Ltd
8.05M
0.4%
+324.11K
+4.20%
Jun 30, 2025
RBC Capital Markets Wealth Management
6.99M
0.34%
+740.61K
+11.84%
Jun 30, 2025
Holocene Advisors, LP
5.61M
0.28%
+304.49K
+5.74%
Jun 30, 2025
State Street Investment Management (US)
6.71M
0.33%
-258.77K
-3.71%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
VanEck Pharmaceutical ETF
10.83%
The Opal International Dividend Income ETF
4.41%
Sound Equity Dividend Income ETF
3.97%
Keating Active ETF
3.88%
USCF Dividend Income Fund
3.83%
Brandes International ETF
2.87%
Altrius Global Dividend ETF
2.58%
Fidelity Blue Chip Value ETF
1.6%
Lattice Hartford Mltfctr Dev Mkts (ex-US) Str ETF
1.17%
Avantis International Large Cap Value ETF
1.02%
View more
VanEck Pharmaceutical ETF
Proportion10.83%
The Opal International Dividend Income ETF
Proportion4.41%
Sound Equity Dividend Income ETF
Proportion3.97%
Keating Active ETF
Proportion3.88%
USCF Dividend Income Fund
Proportion3.83%
Brandes International ETF
Proportion2.87%
Altrius Global Dividend ETF
Proportion2.58%
Fidelity Blue Chip Value ETF
Proportion1.6%
Lattice Hartford Mltfctr Dev Mkts (ex-US) Str ETF
Proportion1.17%
Avantis International Large Cap Value ETF
Proportion1.02%
Dividend
A total of
20.79B
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Feb 05, 2025
GSK.NB Interim Cash Dividend of gross USD 0.434774 paid on Jul 10, 2025 going ex on May 16, 2025
May 16, 2025
Jul 10, 2025
May 16, 2025
Feb 05, 2025
GSK.NB Interim Cash Dividend of gross USD 0.42996 paid on Oct 09, 2025 going ex on Aug 15, 2025
Aug 15, 2025
Oct 09, 2025
Aug 15, 2025
Feb 05, 2025
GSK.NB Approximate final Cash Dividend of gross USD 0.417088 paid on Jan 08, 2026 going ex on Nov 14, 2025
Nov 14, 2025
Jan 08, 2026
Nov 14, 2025
Feb 05, 2025
GSK.NB Interim Cash Dividend of gross USD 0.407568 paid on Apr 10, 2025 going ex on Feb 21, 2025
Feb 21, 2025
Apr 10, 2025
Feb 21, 2025
Oct 30, 2024
GSK.NB Final Cash Dividend of gross USD 0.376892 paid on Jan 09, 2025 going ex on Nov 15, 2024
Nov 15, 2024
Jan 09, 2025
Nov 15, 2024
Jul 31, 2024
GSK.NB Interim Cash Dividend of gross USD 0.392813 paid on Oct 10, 2024 going ex on Aug 16, 2024
Aug 16, 2024
Oct 10, 2024
Aug 16, 2024
May 01, 2024
GSK.NB Interim Cash Dividend of gross USD 0.384301 paid on Jul 11, 2024 going ex on May 16, 2024
May 17, 2024
Jul 11, 2024
May 16, 2024
Feb 01, 2024
GSK.NB Interim Cash Dividend of gross USD 0.404885 paid on Apr 11, 2024 going ex on Feb 22, 2024
Feb 23, 2024
Apr 11, 2024
Feb 22, 2024
Nov 01, 2023
GSK.NB Interim Cash Dividend of gross USD 0.356356 paid on Jan 11, 2024 going ex on Nov 16, 2023
Nov 17, 2023
Jan 11, 2024
Nov 16, 2023
Jul 26, 2023
GSK.NB Interim Cash Dividend of gross USD 0.343532 paid on Oct 12, 2023 going ex on Aug 17, 2023
Aug 18, 2023
Oct 12, 2023
Aug 17, 2023
View more
Stock Split
Date
Type
Ratio
Jun 24, 2022
Merger
5→4
Jun 24, 2022
Merger
5→4
Jun 24, 2022
Merger
5→4
Jun 24, 2022
Merger
5→4
Date
Type
Ratio
Jun 24, 2022
Merger
5→4
Jun 24, 2022
Merger
5→4
Jun 24, 2022
Merger
5→4
Jun 24, 2022
Merger
5→4
FAQs
Who are the top five shareholders of GSK plc?
The top five shareholders of GSK plc are:
Dodge & Cox holds 78.76M shares, accounting for 3.87% of the total shares.
Fidelity Management & Research Company LLC holds 51.48M shares, accounting for 2.53% of the total shares.
Fisher Investments holds 31.34M shares, accounting for 1.54% of the total shares.
PRIMECAP Management Company holds 27.73M shares, accounting for 1.36% of the total shares.
JTC Employer Solutions Trusteee Ltd holds 15.00M shares, accounting for 0.74% of the total shares.
Dodge & Cox holds 78.76M shares, accounting for 3.87% of the total shares.
Fidelity Management & Research Company LLC holds 51.48M shares, accounting for 2.53% of the total shares.
Fisher Investments holds 31.34M shares, accounting for 1.54% of the total shares.
PRIMECAP Management Company holds 27.73M shares, accounting for 1.36% of the total shares.
JTC Employer Solutions Trusteee Ltd holds 15.00M shares, accounting for 0.74% of the total shares.
What are the top three shareholder types of GSK plc?
The top three shareholder types of GSK plc are:
Dodge & Cox
Fidelity Management & Research Company LLC
Fisher Investments
Dodge & Cox
Fidelity Management & Research Company LLC
Fisher Investments
How many institutions hold shares of GSK plc (GSK)?
As of 2025Q3, 1474 institutions hold shares of GSK plc, with a combined market value of approximately 388.63M, accounting for 19.14% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 0.60%.
What is the biggest source of revenue for GSK plc?
In FY2025Q2, the -- business generated the highest revenue for GSK plc, amounting to -- and accounting for --% of total revenue.
